V.I. Technologies, Inc.


Aug 16, 00

08:30 ET Doros Platika, M.D. Elected to VITEX Board

 
Aug 04, 00

08:30 ET VITEX Reports Second Quarter 2000 Results

 
Aug 01, 00

09:04 ET Vitex and Red Cross Extend Transfusion Plasma Contract

 
Jul 10, 00

09:26 ET Vitex Releases New Data on INACTINE(TM)-Treated Red Cells at International Society of Blood Transfusion (ISBT) Meeting

 
May 31, 00

09:13 ET James A. Moose Joins VITEX to Lead Plasma Operations

 
May 15, 00

08:31 ET Vitex Strengthens Clinical and Regulatory Management Team

 
May 04, 00

08:31 ET V. I. Technologies (VITEX) Reports First Quarter 2000 Results

 
May 03, 00

08:31 ET Medicare Initiates Reimbursement for VITEX's PLAS+(R)SD

 
Apr 25, 00

11:35 ET Amersham Pharmacia Biotech to Market VITEX's INACTINE(TM) Technology For Biopharmaceutical, Transgenic and Plasma Fractionation Applications

 
Apr 24, 00

08:29 ET VITEX Appoints David C. Dlesk Executive Vice President, Chief Business Officer for INACTINE(TM)

 
Apr 04, 00

08:30 ET V.I. Technologies (VITEX) Initiates Pivotal Trial of Next Generation Plasma Product

 
Mar 27, 00

15:10 ET V. I. Technologies (VITEX) Announces Relocation of its Headquarters to Boston

 
Jan 21, 00

08:15 ET V. I. Technologies (VITEX) Reports Fourth Quarter Results

 
Jan 12, 00

08:30 ET VITEX Announces $65 Million Extension of Bayer Agreement

 
Dec 06, 99

08:15 ET Pall Makes $3.0 Million Milestone Investment in VITEX; Payment Triggered with Initiation of Red Blood Cell Clinical Trials

 
Nov 15, 99

08:05 ET V.I. Technologies and Pentose Pharmaceuticals Complete Merger

 
Oct 19, 99

14:49 ET V. I. Technologies, Inc. (VITEX) Reports Third Quarter Results

 
Sep 30, 99

17:12 ET American Red Cross Accelerates Conversion to Plas+(R)SD

 
Aug 30, 99

16:15 ET Vitex Files With the FDA for Expanded Safety Step in the Manufacture Of PLAS+(R)SD

 
Aug 12, 99

08:30 ET VITEX Files With the FDA to Commence Clinical Trials of New "Universal" Plasma

 
Aug 06, 99

17:31 ET American Red Cross Agreement With Novation Expands Access to VITEX'S PLAS+(R)SD

 
Jul 20, 99

08:02 ET V. I. Technologies, Inc. (VITEX) Reports Second Quarter Results

 
Jul 14, 99

16:15 ET VITEX Completes Assessment of PLAS+SD Recall

 
Jun 29, 99

10:08 ET VITEX Adds Additional Safety Step In PLAS+SD

 
Jun 16, 99

12:31 ET V.I. Technologies, Inc. (VITEX) Receives Canadian Approval for PLAS+SD

 
May 12, 99

08:04 ET VITEX Completes Voluntary Recall and Implements Additional Viral Safety Testing

 
Apr 20, 99

15:10 ET V.I. Technologies, Inc. (VITEX) Reports First Quarter Profit

 
Apr 16, 99

16:04 ET VITEX Initiates Precautionary Safety Steps and Voluntary Recall

 
Mar 15, 99

13:18 ET VITEX Announces Expanded Distribution of PLAS+(R)SD

 
Feb 23, 99

08:28 ET Vitex to Present Preclinical Data on Red Blood Cell Program At The Blood Safety and Screening Conference

 
Jan 19, 99

07:31 ET V. I. Technologies, Inc. (VITEX) Reports Fourth Quarter Profit of $1.0 Million

 
Dec 21, 98

07:05 ET Vitex Receives $50 Million Minimum Order from the American Red Cross

 


Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2005 PR Newswire Association LLC. ALL Rights Reserved.
A United Business Media company.